Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild type metastatic colorectal cancer in the United States.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.1982181
Abstract: AIM To compare the cost of biweekly regimens of first-line (1L) treatments of cetuximab-FOLFIRI versus panitumumab-FOLFOX in patients with Kirsten's rat sarcoma wild type (KRAS WT) metastatic colorectal cancer (mCRC) in the US, across varying… read more here.
Keywords: cetuximab folfiri; cost; panitumumab folfox;